Sandell Scott D's Form 4 filing
Crescent Biopharma, Inc. (CBIO) · filed Jan 4, 2023
- Accession no.
- 0001209191-23-001186
- Filed
- Jan 4, 2023
- Trade date
- Dec 30, 2022-Jan 4, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.19M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sandell Scott DCIK 0001237289 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 30, 2022 | Common Stock | SSaleDisposed | −66,690 | $3.02 | −$201,403.8 | 4,928,974 | Indirect | |
| Dec 30, 2022 | Common Stock | SSaleDisposed | −54,645 | $3.02 | −$165,027.9 | 4,038,732 | Indirect | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −96,084 | $2.99 | −$287,291.16 | 4,832,890 | Indirect | |
| Jan 3, 2023 | Common Stock | SSaleDisposed | −78,730 | $2.99 | −$235,402.7 | 3,960,002 | Indirect | |
| Jan 4, 2023 | Common Stock | SSaleDisposed | −56,054 | $2.91 | −$163,117.14 | 4,776,836 | Indirect | |
| Jan 4, 2023 | Common Stock | SSaleDisposed | −45,930 | $2.91 | −$133,656.3 | 3,914,072 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.